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Abstract
Background: In resource-limited settings, such as Kenya, access to CD4 testing is limited. Therefore, evaluation of
less expensive laboratory diagnostics is urgently needed to diagnose immuno-suppression in children.
Objectives: To evaluate utility of total lymphocyte count (TLC) as surrogate marker for CD4 count in HIV-infected
children.
Methods: This was a hospital based retrospective study conducted in three HIV clinics in Kisumu and Nairobi in
Kenya. TLC, CD4 count and CD4 percent data were abstracted from hospital records of 487 antiretroviral-naïve HIV-
infected children aged 1 month - 12 years.
Results: TLC and CD4 count were positively correlated (r = 0.66, p < 0.001) with highest correlation seen in
children with severe immuno-suppression (r = 0.72, p < 0.001) and children >59 months of age (r = 0.68, p <
0.001). Children were considered to have severe immuno-suppression if they met the following WHO set CD4
count thresholds: age below 12 months (CD4 counts < 1500 cells/mm
3), age 12-35 months (CD4 count < 750
cells/mm3), age 36-59 months (CD4 count < 350 cells/mm
3, and age above 59 months (CD4 count < 200 cells/
mm
3). WHO recommended TLC threshold values for severe immuno-suppression of 4000, 3000, 2500 and 2000
cells/mm
3 for age categories <12, 12-35, 36-59 and >59 months had low sensitivity of 25%, 23%, 33% and 62%
respectively in predicting severe immuno-suppression using CD4 count as gold standard. Raising TLC thresholds to
7000, 6000, 4500 and 3000 cells/mm
3 for each of the stated age categories increased sensitivity to 71%, 64%, 56%
and 86%, with positive predictive values of 85%, 61%, 37%, 68% respectively but reduced specificity to 73%, 62%,
54% and 68% with negative predictive values of 54%, 65%, 71% and 87% respectively.
Conclusion: TLC is positively correlated with absolute CD4 count in children but current WHO age-specific
thresholds had low sensitivity to identify severely immunosuppressed Kenyan children. Sensitivity and therefore
utility of TLC to identify immuno-suppressed children may be improved by raising the TLC cut off levels across the
various age categories.
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Background
There are an estimated 200,000 HIV-1 infected children
in Kenya the majority of whom acquired the infection
perinatally [1,2]. Without treatment, the mortality of
these children in Kenya and similar resource-poor set-
tings approaches 50% by the age of 2 years, with most
deaths attributable to infectious illnesses and failure to
thrive [3-6]. Recent scale-up of highly active antiretro-
viral therapy (HAART) has resulted in improved survi-
val, however less than 30% of eligible children are
currently receiving HAART [7-10]. Factors that under-
mine further expansion of pediatric HAART coverage in
the Kenyan context include late diagnosis, lack of health
personnel trained in antiretroviral therapy (ART) deliv-
ery and limited laboratory infrastructure for CD4 testing
[2]. The critical role of CD4 cell count/percent in
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any medium, provided the original work is properly cited.predicting clinical progression of pediatric HIV-1 is well
described [11-13]. The diagnostic work-up of HIV-1
infected children is considered incomplete without
review of CD4 results despite the fact that this test is
not routinely available in most rural Kenyan settings
that bear the greatest burden of pediatric HIV. There
are an estimated 100 machines for CD4 testing (FACS-
Count
® or FACSCalibre
®)i nK e n y ao fw h i c ho n l y3 5
are located in public health facilities which serve the
majority of HIV-1 infected children, while the remainder
are found in large private hospitals and clinics, largely in
urban settings. The cost of performing a CD4 count in
Kenya is estimated at US$12 which is at least 4 times
higher than that of a total lymphocyte count. In 2006
the World Health Organization (WHO) recommended
the use of total lymphocyte count (TLC) as a guide for
initiating ART in children with WHO clinical stage 2
who are aged 8 years and below in settings where CD4
counts are not available [14]. In adult studies, correla-
tion between the TLC and CD4 counts ranged from
0.64 to 0.78, and appeared to be stronger for patients
with advanced disease [15-18].
The sensitivity of the recommended TLC levels of
<1200 cells/mm
3 for predicting CD4 counts below 200
cells/mm
3 in adult studies has been however found to
vary widely from 38% to 75% while the positive predic-
tive value has ranged between 64% to 88%[16-19]. A
sensitivity of 75% means that the recommended TLC
cut off will only detect three quarters of those with true
CD4-defined immuno-suppression and miss one quarter.
O nt h eo t h e rh a n dap o s i t i v ep r e d i c t i v ev a l u eo f8 8 %
implies that among children found to have immuno-
suppression by a given TLC cut-off, 88% will meet the
CD4 criteria for immuno-suppression [20]. Given the
aggressive nature of pediatric HIV, any diagnostic test
employed must have very high sensitivity since missing
a diagnosis of severe immuno-suppression would result
in increased mortality [3]. On the other hand low posi-
tive predictive value would lead to misclassification with
children who otherwise have good immunity being cate-
gorized as severely immunosuppressed and inadvertently
started on HAART, thus increasing costs and risk of
toxicity. A meta-analysis by Dunn on a large group of
children in US and Europe found TLC <2500 cells/mm
3
or CD4 percent <20% to be associated with high mortal-
ity [21].
As part of the Kenya’s efforts to meet the recently
published PEPAR II goals, an estimated 100,000 children
need to be newly initiated on HAART before 2013 [22].
In order to realize this goal, new treatment centers need
to be established and some of these may not immedi-
ately have access to routine CD4 testing. Hence it is
pertinent” to validate the use of TLC as surrogate for
CD4 counts in local settings. This is especially critical
s i n c em o s te x i s t i n gd a t aa r el a r g e l yd r a w nf r o mt h eU S
and Western Europe and may not be directly applicable
to local settings. Furthermore there is need for region
specific validation of CD4 and TLC counts changes both
“Pre-HAART” and on HAART. Our study was designed
to determine the diagnostic utility of TLC as a surrogate
for CD4 counts and correlation between TLC and CD4
counts in Kenya children attending HIV clinics in three
sites.
Methods
This was a retrospective hospital based cross-sectional
survey, carried out at three hospitals in Kenya; Kenyatta
National Referral Hospital (KNH) in Nairobi, Mbagathi
District Hospital (MDH) in Nairobi, and New Nyanza
Provincial General Hospital (NNPGH) in Kisumu, wes-
tern Kenya. All HIV infected children aged between one
month and twelve years on follow-up in the comprehen-
sive HIV care clinics (CCC) at the three hospitals who
had medical records on CD4 count and total lympho-
cyte at enrollment into care prior to initiation of ART
were eligible for inclusion in the study.
The medical records of children receiving care
between January 2004 and July 2006 were reviewed.
“Evidence of HIV status was sought, specifically, by doc-
umentation of a positive HIV antibody test for children
above 18 months, or positive HIV PCR test result for
children below 18 months. For eligible children, data on
age, sex, WHO clinical stage, absolute CD4 count and
TLC data prior to ART initiation was abstracted from
medical records. Any child missing any of these data
was excluded. Children were consecutively enrolled
from each site until the desired sample size was
achieved. We excluded children under the age of one
month due to uncertainty of HIV diagnosis in this
group.
Approval to conduct the study was sought from the
Ethical Review Committee of KNH which is the teach-
ing hospital of the University of Nairobi, as well as from
the administration of the Mbagathi and New Nyanza
Hospitals. Confidentiality was maintained for all
abstracted patient records which were identified only by
number stored in a secure computer.
Statistical Methods
Data was analyzed using STATA version 9.2. Correla-
tion between all pairs of TLC, CD4 cell count, and TLC
and CD4% (all as continuous variables) were determined
using Spearman’s correlation coefficient. Children were
then categorized into four age groups <12, 12-35, 36-59
and >59 months. We also categorized children by pre-
sence or absence of severe immuno-suppression based
on WHO 2006 age specific immunologic categorizations
as follows: age <12 months CD4 < versus ≥ 1500 cells/
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3, 12-35 months CD4 < versus ≥ 750 cells/mm
3,3 6 -
59 months CD4 < versus ≥ 350 cells/mm
3 and >59
months CD4 < versus ≥ 200 cells/mm
3. Similarly severe
immune-suppression by CD4 percentage was defined as
CD4% <25%, <20%, <15% and <15% for ages <12
months, 12-35, 36-59, and >59 months respectively [14].
TLC was categorized using WHO age-specific TLC
thresholds defining presence or absence of immuno-sup-
pression stratified by the same age categories as follows:




3 respectively [14]. The sensitivity, specifi-
city, positive predictive value (PPV) negative predictive
values (NPV) of the WHO TLC cut-offs in predicting
severe immune-suppression as defined by WHO CD4
thresholds were determined. Data was analyzed to deter-
mine the optimal TLC cut-offs that provide highest sen-
sitivity and specificity for predicting severe immune-
suppression.
Results
We identified 487 ART naive HIV infected children who
had complete records, including 125 children from
N N P G H ,1 8 6f r o mM D Ha n d1 7 6f r o mK N H .T w o
hundred and twenty three (46%) were female and the
median age was 36 months (IQR 18-68, Table 1).
Clinical Parameters and CD4 Profile
Prior to starting ART 95 (20%) children had WHO clin-
ical stage 1 or 2 disease, while 392 (80%) had stage 3 or
4 disease (Table 1). The median CD4 count was 537
cells/mm
3 (IQR 216-992), median CD4 percentage
11.6% (IQR 5.7-19), and median TLC (TLC) was 4500
cells/mm
3 (IQR 2700-6655). The median CD4 count
decreased with rising age, and was 1060, 777, 565 and
226 cells/mm
3 in children of age <12, 12-35, 36-59 and
>59 months respectively. The corresponding median
CD4% for children in the four age categories in ascend-
ing order was 17.5%, 12.3%, 11.9%, and 7.4%. The med-
ian TLC was 6895, 6000, 4513 and 2577 cells/mm
3
among children of the four age groups (Table 2). We
categorized children as either severely immunosup-
pressed or not based on age-specific thresholds of CD4
count, CD4%, and TLC based on WHO 2006 classifica-
tions (Table 2).
Correlation between CD4 Counts and Total Lymphocyte
Counts
Correlation between absolute CD4 counts and the TLC
for the whole study population was 0.66 (Spearman cor-
relation coefficient). In the individual sites correlation
w a sa sf o l l o w s :K N H( 0 . 7 6 ) ,M D H( 0 . 5 5 ) ,a n dN N P G H
(0.54). Correlation between CD4 counts and TLC was
then explored among different age groups, and stratified
by presence or absence of severe immuno-suppression.
Correlation among children <12 months was 0.54, for
12-35 months it was 0.44, for 36-59 months, 0.38, and
for >59 months correlation was 0.68. The strongest cor-
relation was seen in the oldest group of children (>59
months). Correlation between CD4 count and TLC
among children who were severely immunosuppressed
was 0.72 which was higher than their counterparts with-
out severe immuno-suppression correlation 0.63. Overall
correlation between TLC and CD4% was weak (r =
0.06).
Diagnostic Utility of TLC to identify Severely Immuno-
suppressed Children
To test the utility of TLC as a surrogate marker for CD4
count, sensitivity, specificity, PPV and NPV of TLC was
determined using WHO 2006 recommended cut off
values for absolute CD4 count as the gold standard.
Table 3 shows the proportion of children classified
according to presence of severe immuno-suppression as
defined by both CD4 count and TLC and stratified by
age while table 4 shows the same with additional stratifi-
cation by WHO clinical stage. The sensitivity of WHO
recommended age-specific TLC thresholds to identify
severely immune-suppressed children was low, ranging
from 23 to 62% while specificity was high ranging from
83% to 100%. PPV was high ranging from 68% to 100%
while NPV ranged from 37% to 74% (Table 5).
Raising Cut off Values of TLC to Improve Diagnostic
Utility
Since the recommended WHO TLC cut offs for identi-
fying severe immuno-suppression in all age categories
had low sensitivity, we explored whether raising the
TLC cut offs would improve the sensitivity without
unduly compromising the specificity. As an alternative
Table 1 Descriptive Characteristics of Study Population (n
= 487)
Characteristic Frequency (%) or Median (IQR)
Hospital
New Nyanza Provincial Hospital 125 (25.7)
Mbagathi District Hospital 186 (38.2)
Kenyatta National Hospital 176 (36.1)
Female 223 (46)
Age in months 36 (18-68)
Age group
<12 months 82 (17)
12-35 months 129 (26)
36-59 months 118 (24)
>59 months 158 (32)
WHO Clinical Stage
1 and 2 96 (19.7)
3 and 4 390 (80.2)
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neously evaluating how sensitivity and specificity vary as
the cutoff point is changed, we plotted sensitivity and
specificity against various TLC cut off points. The plots
for different age groups were used to determine optimal
cut off points which are defined as the TLC value that
yields the highest sensitivity while maintaining accepta-
ble specificity (Figure 1). For age category <12 months,
raising the TLC cut off from WHO 4000 cells/mm
3 to
7000 cells/mm
3 improved the sensitivity from 25% to
71%, but decreased specificity from 100% to 73% (Table
4). Similarly for age group 12-35 months, raising the
TLC cut off value from 3000 cells/mm
3 to 6000 cells/
mm
3 improved the sensitivity from 23% to 65% accom-
panied by a decreased specificity from 98% to 62%. For
age category 36-59 months, raising the TLC cut off
value from 2500 cells/mm
3 to 4500 cells/mm
3 would
improve the sensitivity from 33% to approximately 60%.
F o ra g ec a t e g o r y> 5 9m o n t h s ,r a i s i n gt h eT L Cc u to f f
from 2000 cells/mm
3 to 3000 cells/mm
3 would improve
the sensitivity from 62% to 86% but lead to a loss in
specificity from 83% to 68%. A mean value across age
groups was computed for each variable at the current
WHO TLC threshold, and at new proposed threshold.
The mean sensitivity improved considerably from 36%
to 71%, mean specificity decreased from 93% to 64%,
mean PPV dropped from 84% to 63%, mean NPV
improved from 61% to 69% (Table 5).
Discussion
Several studies in adults and a few in children have sug-
gested that TLC may be used as surrogates of CD4+ T
cell count in HIV infected patients [17,18,22,23]. Our
study was designed to evaluate the utility of TLC to
identify immuno-suppression in HIV infected children
from three pediatric HIV care centers in Kenya. In our
study population, TLC was positively correlated with
CD4 count (overall r = 0.66), with stronger correlation
among children with severely depressed CD4 counts.
We found the WHO 2006 TLC thresholds defining
immuno-suppression to have low sensitivity but high
specificity for detecting severely depressed CD4 count in
these Kenyan children, and sensitivity was lowest among
young children under 5 years (<34%). In contrast to the
CD4 count, there was very poor correlation between
TLC and CD4% (r = 0.06) similar to weak correlation (r
= 0.01) reported by Musoke in Ugandan children [24].
The WHO recommendations for use of TLC as surro-
gate marker for CD4 count for decision in initiating
H A A R Ti nc h i l d r e ni sb a s e du p o nt h ep r e m i s et h a t
TLC is easily available and easy to perform relative to
the CD4 assays. As a good surrogate marker the TLC
cut-off values should be highly sensitive in identifying
children of low CD4 count requiring HAART. Stated
differently, a good tool should not miss immuno-sup-
pressed children who are at highest risk of mortality. In
our study population, between 67 and 75% of the chil-
dren aged below 5 years who require ART would have
been missed by the WHO TLC thresholds used suggest-
ing low utility in HIV program settings.
In order to improve the utility of TLC we explored
raising the cut-off values to levels higher than those
recommended by the WHO 2006 guidelines. We used
the point of maximal sensitivity with least compromise
in specificity as the new optimal TLC cutoff point. We
thus selected increased TLC thresholds that would give
optimized combination of good sensitivity, with accepta-
ble specificity and PPV. This resulted in improved mean
sensitivity of the TLC from 36% to 71% for detection of
severe immuno-suppression in our population, while













<12 1060 (604-1590) 17.5 (10.5-23.6) 6895 (4875-8670)) 82
12-35 777 (400-1123) 12.3 (7.2-18) 6000 (3770-8035) 129
36-59 565 (250-880) 11.9 (5-8-21.9) 4513 (3289-5511) 118
>59 226 (35-430) 7.4 (1.6-14) 2577 (1675-4100) 158
ALL 537 (216-992) 11.6 ((5.7-190) 4500 (2700-6655) 487
Table 3 Proportion of Children Immuno-suppressed by Age Category
Age group in
months
Severely depressed CD4 count
Frequency (%)






<12 56 (68.3) 62 (48.1) 13 (15.9) 82
12-35 62 (48.1) 102 (79.1) 15 (12.4) 129
36-59 39 (33.3) 75 (63.6) 19 (16.1) 118
>59 69 (43.7) 127 (80.4) 58 (36.7) 158
ALL 226 (46.2) 371 (76.2) 105(21.6) 487
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(mean 63%). Examining the effect of raising TLC thresh-
old more closely, in the age category <12 months, the
proposed raised TLC threshold of 7000 cells/mm
3
yielded improved sensitivity of 71% (previously 25%),
meaning that new threshold would identify 7 of 10
immuno-suppressed children needing ART compared to
2 of 10 identified by the previous threshold of 4000
cells/mm
3. Given that HIV is uniformly fatal in the
absence of interventions, improved sensitivities for the
raised TLC threshold favors the use of TLC as a screen-
ing tool for severe immuno-suppression in settings
where CD4 monitoring is not easily accessible.
On the other hand, further increasing TLC thresholds
beyond the optimized levels we selected based on our
cohort data would grossly decrease specificity and PPV
for relatively little incremental gain in sensitivity. This
would result in unacceptably high numbers of children
who are actually not severely immune-depleted being
misclassified and started on ART earlier than they
require, exposing them unnecessarily to the problems
associated with ART including adverse drug effects,
development of antiretroviral drug resistance well as
increasing the cost of running programs purchase of
expensive medications.
Considering that the clinical staging of disease is also
employed together with the immunological criteria in
order to initiate HAART, in this study we recommend
raising the TLC cut-offs from the current WHO recom-
mended TLC cut-off values. Raising TLC cut off values
to improve sensitivity and enable TLC to be used as a
better screening tool has been previously proposed by
adult studies in Uganda and Kenya [17,18]. A Ugandan
study in adults found TLC values of 2100 cells/mm
3 to
best predict CD4 < 200 cells/mm
3 (sensitivity 83%, spe-
cificity 77%, PPV 92%, NPV 57%) which was superior to
a cut-off value of 1200 [19]. In Kenyan adults, raising
the TLC cut off value from the recommended 1200
cells/mm3 to 1900 cells/mm3 resulted in improved diag-
nostic utility for predicting CD4 < 200 cells/mm
3 (sensi-
tivity 81%, specificity 90%, PPV 90%, NPV 80%) [17].
The higher cut off value for TLC required to improve
Table 4 Proportion of Children Immuno-suppressed by Age Category stratified by WHO clinical stage.
WHO Clinical Stage Age group in months Severely depressed CD4 count Frequency (%) Depressed TLC Frequency (%) No. of Children
Stage 1-2 <12 12 (60) 1 (5) 20
12-35 9 *(35) 1 (3.8) 26
36-59 4 (13) 5 (16.1) 31
>59 5 (26) 7 (36.8) 19
All 30 (31) 14 (14.6) 96
Stage 3-4 <12 44 (71) 12 (19.4) 62
12-35 52 (51) 14 (13.7) 102
36-59 35 (40) 14 (16.1) 87
>59 64 (46) 51 (36.7) 139
All 195 (50) 91 (23.3) 390
ALL 225 (46) 105 (21.6) 486*
*One child in this age category did not have WHO clinical stage excluded from this table
Table 5 Sensitivity, Specificity, PPV and NPV of Current WHO TLC thresholds and Proposed new raised TLC thresholds
to Identify Severely Immuno-suppressed Children
Age group in months Current WHO TLC threshold (cells/mm
3) Sensitivity Specificity PPV
a NPV
b No. of children
<12 4000 25 100 100 37 82
12-35 3000 23 98 93 58 129
36-59 2500 33 92 68 74 118






Age group in months Proposed Optimal TLC Sensitivity Specificity PPV NPV No. of Children
<12 7000 71 73 85 54 82
12-35 6000 65 62 61 65 129
36-59 4500 60 54 37 71 118
>59 3000 86 68 68 87 158
ALL 71 64 63 69 487
aPPV = positive predictive value
bNPV = negative predictive value
cMean value for the four age groups
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higher burden of background infectious disease. WHO
recommended cut-off TLC values were largely driven by
available data from the United States. It has been pre-
viously shown that normal values of T cell subset
among African children may differ from those of other
populations. A study in Guinea Bissau found healthy
children under the age of 2 years to have lower CD4%
and CD4/CD8 ratios and higher CD8% than their coun-
terparts from developed countries [25].
Mahajan et al explored the utility of changes in TLC
as a surrogate for changes in CD4 counts following
HAART initiation among HIV-infected adults in India
[26]. The main strength of this study was the multiple
longitudinal TLC measurements with corresponding
CD4 counts that allowed a comparison of changes as
o p p o s e dt os i n g l ev a l u ea si st h ec a s ei no u rs t u d y .T h e
study showed that an increase in TLC reliably predicts a
corresponding rise in CD4 count but a falling TLC did
n o ts i m i l a r l yp r e d i c tad r o pi nC D 4c o u n t( 9 8 %v e r s u s
63% positive and negative predictive values respectively.
The study also noted substantial individual variation
making it more difficult for a single TLC measurement
to predict the actual quantitative CD4 change further
highlighting the importance of multiple measurements
[26].
The poor correlation between TLC and CD4% in chil-
dren in our study is of concern given that CD4% is
widely used in children to predict disease progression
and is included in WHO guidelines for initiating
HAART[14]. Moreover, CD4% has been found to be an
important prognostic marker even post HAART initia-
tion in a large cohort of HIV Zambian infected children
[27]. It is notable that in the Zambian study, low CD4%
was associated with mortality mainly among children <
18 months but not in those aged 18-59 months.
Figure 1 Optimal sensitivity and specificity for various TLC cut-offs by Age Group. Sensitivity and specificity of TLC to detect severe
immune-suppression was plotted against various total lymphocyte count (cells/mm
3) cut-offs for four different age groups. a) Below 12 months
b) 12-35 months c) 36-59 months and d) 60 months and above
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children in Kwazulu Natal, CD4% was not predictor of
mortality underscoring the fact that TLC may still be
relevant despite lacking direct association with CD4%
[28].
An important group of HIV-infected children are
those co-infected with tuberculosis as well as other con-
ditions associated with leukocyte changes independent
of HIV. Although no pediatric literature was found on
this subject, among adults, Martin et al found strong
correlation (R = 0.7) between TLC and CD4 count both
at baseline and after 1 month of TB treatment in HIV-
TB co-infected South African adults [29]. In this study
TLC of between 1300-1500/ml was highly predictive of
CD4 count< 200/ul.
In a broad context of expanding HIV treatment in set-
tings with limited laboratory recourses, the DART trial,
a randomized non-inferiority trial comparing clinically
driven monitoring (CDM) verses laboratory and clinical
monitoring (LCM) found clinically 5 year survival rates
of 87% verses 90% in CDM and LCM arms respectively
[30]. While 12-weekly CD4 monitoring did not impact
disease progression in the first 2 years of ART, after 2
years a small but significant increase in clinical disease
progression was found in favour of the LCM. This clini-
cal progression may be attributed to delay in switching
to 2
nd line ART in the CDM with potential higher resis-
tance. Thus whereas findings of the DART trial high-
light the importance of CD4 testing in patients it
remains crucial to similarly evaluate the role of TLC as
surrogate for CD4 in HAART-treated children.
Conclusions
We conclude that in these Kenyan children TLC was
positively correlated with absolute CD4 count, but cur-
rent WHO age-specific TLC thresholds had low sensi-
tivity to identify those who were severely immuno-
suppressed. Raising the TLC cut-off for all age groups
considerably improved the sensitivity of TLC, retaining
acceptable specificity and PPV, suggesting that at higher
thresholds TLC has good utility as a tool to identify
severely immune-depleted children requiring ART in
settings where CD4 testing is not readily available. Lim-
itations of our study include the modest sample size and
fact that we only obtained single measurements of TLC
and CD4. Our findings suggest that rather than shelve
the use of TLC due to concerns of diagnostic utility,
further research is needed to define optimum cut off
values and should preferably be longitudinal with a
much larger sample size. Considering the significantly
higher cost of performing a CD4 count relative to TLC,
and the limited availability of FACSCOUNT machines
in Kenya, efforts that will lead to adoption of TLC will
remove a major barrier to HAART initiation for HIV
infected children, avert numerous deaths and help the
country meet the targets of PEPfAR II.
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